MetaCap

NanoViricides (NNVC) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 10.2% versus a loss of 71.6%. NanoViricides is the larger company by market cap ($29.1 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NNVC-10.24%TELO-71.56%
+52%-13%-77%
Nov 21, 20251 yearNov 20, 2026
NNVC0.00%TELO-92.72%
+146%+21%-104%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NNVC versus TELO key metrics
MetricNNVCTELO
Share price$1.14$0.364
Market cap$29.13M$26.82M
1-day change-2.56%-17.24%
YTD return+0.88%-72.63%
1-year return-10.24%-71.56%
5-year return-76.54%—
EPS (TTM)$-0.53$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-8.22M$-10.41M
52-week high$1.93$1.58
52-week low$0.85$0.353
Distance from 52-week high-40.93%-76.96%
Analyst consensusstrong_buynone
Avg. price target upside+426.32%+998.90%
Average volume356.86K126.14K
Shares outstanding25.55M73.68M
Employees7—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed TELO by 61.3 percentage points over the past year.

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

NNVC vs TELO FAQ

Which is bigger, NanoViricides or Telomir Pharmaceuticals?

NanoViricides (NNVC) is larger, with a market capitalization of $29.13M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, NNVC or TELO?

NNVC returned -10.24% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are NanoViricides and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons